Council Directive 92/66/EEC of 14 July 1992 introducing Community measures for the control of Newcastle disease

Print Options
PrintThe Whole
Directive
PrintThe Whole
Annex
PrintThe Whole
Chapter
PrintThis
Division
only
Changes over time for: Procedure


Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Status:
EU Directives are published on this site to aid cross referencing from UK legislation. Since IP completion day (31 December 2020 11.00 p.m.) no amendments have been applied to this version.
ProcedureU.K.
(a)
Dispense 0,025 ml PBS into all wells of a plastic microtitre plate (with V-bottomed wells).
(b)
Place 0,025 ml of serum into first well of plate.
(c)
Use microtitration diluter to make two-fold dilutions of serum across plate.
(d)
Add 0,025 ml of diluted allantoic fluid containing 4 or 8 HAU.
(e)
Mix by tapping and place plate at 4 °C for a minimum of 60 minutes or room temperature for a minimum of 30 minutes.
(f)
Add 0,025 ml 1 % RBCs to all wells.
(g)
Mix by gentle tapping and place at 4 °C.
(h)
Plates are read after 30-40 minutes when control RBCs are settled. This is done by tilting and observing the presence or absence of tear-shaped streaming at the same rate as control wells containing RBCs (0,025 ml) and PBCs (0,05 ml) only.
(i)
The HI titre is the highest dilution of antiserum causing complete inhibition of 4 or 8 units of virus (an HA titration to confirm the presence of the required HAU should be included in each test).
(j)
The validity of the results is dependent on obtaining a titre of less than 23 for 4 HAU or 22 for 8 HAU with the negative control serum and a titre of within one dilution of the known titre of the positive control serum.
Back to top